Is FRMM or IRD more profitable?

Forum Markets has a net margin of 0.00% compared to Opus Genetics' net margin of -892.36%. Forum Markets' return on equity of -242.09% beat Opus Genetics' return on equity. Company Net Margins Return on Equity Return on Assets Forum Markets N/A -242.09% -135.46% Opus Genetics -892.36% -338.88% -191.21%

Does the media refer more to FRMM or IRD?

In the previous week, Opus Genetics had 4 more articles in the media than Forum Markets. MarketBeat recorded 11 mentions for Opus Genetics and 7 mentions for Forum Markets. Forum Markets' average media sentiment score of 0.70 beat Opus Genetics' score of 0.29 indicating that Forum Markets is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Forum Markets 2 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Opus Genetics 0 Very Positive mention(s) 1 Positive mention(s) 6 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral

Do analysts prefer FRMM or AMRN?

Forum Markets presently has a consensus price target of $10.00, indicating a potential upside of 67.79%. Given Forum Markets' higher probable upside, research analysts clearly believe Forum Markets is more favorable than Amarin. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Forum Markets 1 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 1 Strong Buy rating(s) 2.50 Amarin 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 1 Strong Buy rating(s) 2.50

Which has higher valuation and earnings, FRMM or AMRN?

Amarin has higher revenue and earnings than Forum Markets. Amarin is trading at a lower price-to-earnings ratio than Forum Markets, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Forum Markets $9.41M 8.49 -$450.52M -$36.07 N/A Amarin $213.65M 1.46 -$38.80M -$0.65 N/A

Is FRMM or AMRN more profitable?

Forum Markets has a net margin of 0.00% compared to Amarin's net margin of -15.51%. Amarin's return on equity of -2.99% beat Forum Markets' return on equity. Company Net Margins Return on Equity Return on Assets Forum Markets N/A -242.09% -135.46% Amarin -15.51% -2.99% -2.07%

Does the media prefer FRMM or AMRN?

In the previous week, Forum Markets had 4 more articles in the media than Amarin. MarketBeat recorded 7 mentions for Forum Markets and 3 mentions for Amarin. Forum Markets' average media sentiment score of 0.70 beat Amarin's score of 0.40 indicating that Forum Markets is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Forum Markets 2 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Amarin 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Do analysts prefer FRMM or INDP?

Forum Markets currently has a consensus target price of $10.00, indicating a potential upside of 67.79%. Given Forum Markets' stronger consensus rating and higher probable upside, analysts plainly believe Forum Markets is more favorable than Indaptus Therapeutics. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Forum Markets 1 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 1 Strong Buy rating(s) 2.50 Indaptus Therapeutics 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Is FRMM or INDP more profitable?

Forum Markets' return on equity of -242.09% beat Indaptus Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Forum Markets N/A -242.09% -135.46% Indaptus Therapeutics N/A -1,030.07% -299.69%

Does the media favor FATE or FRMM?

In the previous week, Fate Therapeutics had 2 more articles in the media than Forum Markets. MarketBeat recorded 9 mentions for Fate Therapeutics and 7 mentions for Forum Markets. Fate Therapeutics' average media sentiment score of 0.76 beat Forum Markets' score of 0.70 indicating that Fate Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Fate Therapeutics 2 Very Positive mention(s) 1 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Forum Markets 2 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Is LRMR or FRMM more profitable?

Larimar Therapeutics' return on equity of -134.14% beat Forum Markets' return on equity. Company Net Margins Return on Equity Return on Assets Larimar Therapeutics N/A -134.14% -96.00% Forum Markets N/A -242.09% -135.46%

Does the media favor LRMR or FRMM?

In the previous week, Larimar Therapeutics had 4 more articles in the media than Forum Markets. MarketBeat recorded 11 mentions for Larimar Therapeutics and 7 mentions for Forum Markets. Larimar Therapeutics' average media sentiment score of 1.07 beat Forum Markets' score of 0.70 indicating that Larimar Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Larimar Therapeutics 2 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Forum Markets 2 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Forum Markets (FRMM) Competitors

$5.96 +0.06 (+1.02%)

Closing price 07/10/2026 04:00 PM Eastern

Extended Trading

$5.65 -0.31 (-5.20%)

As of 07/10/2026 07:58 PM Eastern

Compare

FRMM vs. IRD, AMRN, INDP, FATE, and LRMR

Should you buy Forum Markets stock or one of its competitors? MarketBeat compares Forum Markets with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Forum Markets include Opus Genetics (IRD), Amarin (AMRN), Indaptus Therapeutics (INDP), Fate Therapeutics (FATE), and Larimar Therapeutics (LRMR). These companies are all part of the "pharmaceutical products" industry.

How does Forum Markets compare to Opus Genetics?

Forum Markets (NASDAQ:FRMM) and Opus Genetics (NASDAQ:IRD) are both small-cap pharmaceutical products companies, but which is the better investment? We will compare the two businesses based on the strength of their media sentiment, institutional ownership, profitability, analyst recommendations, dividends, valuation, earnings and risk.

4.1% of Forum Markets shares are owned by institutional investors. Comparatively, 15.0% of Opus Genetics shares are owned by institutional investors. 15.1% of Forum Markets shares are owned by insiders. Comparatively, 11.7% of Opus Genetics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Forum Markets has a net margin of 0.00% compared to Opus Genetics' net margin of -892.36%. Forum Markets' return on equity of -242.09% beat Opus Genetics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Forum Markets	N/A	-242.09%	-135.46%
Opus Genetics	-892.36%	-338.88%	-191.21%

Forum Markets presently has a consensus target price of $10.00, indicating a potential upside of 67.79%. Opus Genetics has a consensus target price of $10.77, indicating a potential upside of 174.73%. Given Opus Genetics' stronger consensus rating and higher possible upside, analysts plainly believe Opus Genetics is more favorable than Forum Markets.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Forum Markets	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.50
Opus Genetics	1 Sell rating(s)	1 Hold rating(s)	14 Buy rating(s)	1 Strong Buy rating(s)	2.88

In the previous week, Opus Genetics had 4 more articles in the media than Forum Markets. MarketBeat recorded 11 mentions for Opus Genetics and 7 mentions for Forum Markets. Forum Markets' average media sentiment score of 0.70 beat Opus Genetics' score of 0.29 indicating that Forum Markets is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Forum Markets	2 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Opus Genetics	0 Very Positive mention(s)	1 Positive mention(s)	6 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

Forum Markets has a beta of 1.37, meaning that its stock price is 37% more volatile than the broader market. Comparatively, Opus Genetics has a beta of 0.55, meaning that its stock price is 45% less volatile than the broader market.

Opus Genetics has higher revenue and earnings than Forum Markets. Opus Genetics is trading at a lower price-to-earnings ratio than Forum Markets, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Forum Markets	$9.41M	8.49	-$450.52M	-$36.07	N/A
Opus Genetics	$11.98M	27.01	-$49.59M	-$1.33	N/A

Summary

Opus Genetics beats Forum Markets on 9 of the 16 factors compared between the two stocks.

How does Forum Markets compare to Amarin?

Forum Markets (NASDAQ:FRMM) and Amarin (NASDAQ:AMRN) are both small-cap pharmaceutical products companies, but which is the better investment? We will contrast the two businesses based on the strength of their risk, earnings, analyst recommendations, dividends, profitability, media sentiment, institutional ownership and valuation.

4.1% of Forum Markets shares are held by institutional investors. Comparatively, 22.3% of Amarin shares are held by institutional investors. 15.1% of Forum Markets shares are held by company insiders. Comparatively, 4.2% of Amarin shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Forum Markets has a net margin of 0.00% compared to Amarin's net margin of -15.51%. Amarin's return on equity of -2.99% beat Forum Markets' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Forum Markets	N/A	-242.09%	-135.46%
Amarin	-15.51%	-2.99%	-2.07%

In the previous week, Forum Markets had 4 more articles in the media than Amarin. MarketBeat recorded 7 mentions for Forum Markets and 3 mentions for Amarin. Forum Markets' average media sentiment score of 0.70 beat Amarin's score of 0.40 indicating that Forum Markets is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Forum Markets	2 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Amarin	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Amarin has higher revenue and earnings than Forum Markets. Amarin is trading at a lower price-to-earnings ratio than Forum Markets, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Forum Markets	$9.41M	8.49	-$450.52M	-$36.07	N/A
Amarin	$213.65M	1.46	-$38.80M	-$0.65	N/A

Forum Markets presently has a consensus price target of $10.00, indicating a potential upside of 67.79%. Given Forum Markets' higher probable upside, research analysts clearly believe Forum Markets is more favorable than Amarin.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Forum Markets	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.50
Amarin	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	1 Strong Buy rating(s)	2.50

Forum Markets has a beta of 1.37, suggesting that its stock price is 37% more volatile than the broader market. Comparatively, Amarin has a beta of 0.8, suggesting that its stock price is 20% less volatile than the broader market.

Summary

Forum Markets beats Amarin on 9 of the 15 factors compared between the two stocks.

How does Forum Markets compare to Indaptus Therapeutics?

Forum Markets (NASDAQ:FRMM) and Indaptus Therapeutics (NASDAQ:INDP) are both small-cap pharmaceutical products companies, but which is the better business? We will compare the two companies based on the strength of their dividends, valuation, earnings, analyst recommendations, media sentiment, profitability, institutional ownership and risk.

Forum Markets' return on equity of -242.09% beat Indaptus Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Forum Markets	N/A	-242.09%	-135.46%
Indaptus Therapeutics	N/A	-1,030.07%	-299.69%

In the previous week, Forum Markets had 5 more articles in the media than Indaptus Therapeutics. MarketBeat recorded 7 mentions for Forum Markets and 2 mentions for Indaptus Therapeutics. Indaptus Therapeutics' average media sentiment score of 1.44 beat Forum Markets' score of 0.70 indicating that Indaptus Therapeutics is being referred to more favorably in the news media.

Company	Overall Sentiment
Forum Markets	Positive
Indaptus Therapeutics	Positive

Indaptus Therapeutics has lower revenue, but higher earnings than Forum Markets. Indaptus Therapeutics is trading at a lower price-to-earnings ratio than Forum Markets, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Forum Markets	$9.41M	8.49	-$450.52M	-$36.07	N/A
Indaptus Therapeutics	N/A	N/A	-$20.85M	-$15.40	N/A

Forum Markets has a beta of 1.37, meaning that its share price is 37% more volatile than the broader market. Comparatively, Indaptus Therapeutics has a beta of 1.11, meaning that its share price is 11% more volatile than the broader market.

4.1% of Forum Markets shares are held by institutional investors. Comparatively, 7.1% of Indaptus Therapeutics shares are held by institutional investors. 15.1% of Forum Markets shares are held by company insiders. Comparatively, 23.6% of Indaptus Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Forum Markets currently has a consensus target price of $10.00, indicating a potential upside of 67.79%. Given Forum Markets' stronger consensus rating and higher probable upside, analysts plainly believe Forum Markets is more favorable than Indaptus Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Forum Markets	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.50
Indaptus Therapeutics	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Summary

Forum Markets beats Indaptus Therapeutics on 10 of the 15 factors compared between the two stocks.

How does Forum Markets compare to Fate Therapeutics?

Fate Therapeutics (NASDAQ:FATE) and Forum Markets (NASDAQ:FRMM) are both small-cap pharmaceutical products companies, but which is the better stock? We will compare the two companies based on the strength of their risk, institutional ownership, profitability, earnings, valuation, analyst recommendations, media sentiment and dividends.

Fate Therapeutics has higher earnings, but lower revenue than Forum Markets. Fate Therapeutics is trading at a lower price-to-earnings ratio than Forum Markets, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Fate Therapeutics	$6.32M	57.21	-$136.32M	-$1.09	N/A
Forum Markets	$9.41M	8.49	-$450.52M	-$36.07	N/A

Fate Therapeutics presently has a consensus price target of $5.13, suggesting a potential upside of 65.32%. Forum Markets has a consensus price target of $10.00, suggesting a potential upside of 67.79%. Given Forum Markets' stronger consensus rating and higher probable upside, analysts clearly believe Forum Markets is more favorable than Fate Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Fate Therapeutics	1 Sell rating(s)	3 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.29
Forum Markets	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.50

Forum Markets has a net margin of 0.00% compared to Fate Therapeutics' net margin of -2,056.79%. Fate Therapeutics' return on equity of -58.89% beat Forum Markets' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Fate Therapeutics	-2,056.79%	-58.89%	-39.39%
Forum Markets	N/A	-242.09%	-135.46%

In the previous week, Fate Therapeutics had 2 more articles in the media than Forum Markets. MarketBeat recorded 9 mentions for Fate Therapeutics and 7 mentions for Forum Markets. Fate Therapeutics' average media sentiment score of 0.76 beat Forum Markets' score of 0.70 indicating that Fate Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Fate Therapeutics	2 Very Positive mention(s)	1 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Forum Markets	2 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Fate Therapeutics has a beta of 2.51, suggesting that its share price is 151% more volatile than the broader market. Comparatively, Forum Markets has a beta of 1.37, suggesting that its share price is 37% more volatile than the broader market.

97.5% of Fate Therapeutics shares are held by institutional investors. Comparatively, 4.1% of Forum Markets shares are held by institutional investors. 4.7% of Fate Therapeutics shares are held by company insiders. Comparatively, 15.1% of Forum Markets shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Summary

Fate Therapeutics beats Forum Markets on 10 of the 17 factors compared between the two stocks.

How does Forum Markets compare to Larimar Therapeutics?

Larimar Therapeutics (NASDAQ:LRMR) and Forum Markets (NASDAQ:FRMM) are both small-cap pharmaceutical products companies, but which is the better business? We will contrast the two companies based on the strength of their institutional ownership, media sentiment, dividends, profitability, earnings, analyst recommendations, risk and valuation.

Larimar Therapeutics' return on equity of -134.14% beat Forum Markets' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Larimar Therapeutics	N/A	-134.14%	-96.00%
Forum Markets	N/A	-242.09%	-135.46%

91.9% of Larimar Therapeutics shares are held by institutional investors. Comparatively, 4.1% of Forum Markets shares are held by institutional investors. 4.5% of Larimar Therapeutics shares are held by insiders. Comparatively, 15.1% of Forum Markets shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

In the previous week, Larimar Therapeutics had 4 more articles in the media than Forum Markets. MarketBeat recorded 11 mentions for Larimar Therapeutics and 7 mentions for Forum Markets. Larimar Therapeutics' average media sentiment score of 1.07 beat Forum Markets' score of 0.70 indicating that Larimar Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Larimar Therapeutics	2 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Forum Markets	2 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Larimar Therapeutics has a beta of 0.83, suggesting that its stock price is 17% less volatile than the broader market. Comparatively, Forum Markets has a beta of 1.37, suggesting that its stock price is 37% more volatile than the broader market.

Larimar Therapeutics presently has a consensus target price of $12.71, suggesting a potential upside of 197.06%. Forum Markets has a consensus target price of $10.00, suggesting a potential upside of 67.79%. Given Larimar Therapeutics' stronger consensus rating and higher possible upside, research analysts clearly believe Larimar Therapeutics is more favorable than Forum Markets.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Larimar Therapeutics	1 Sell rating(s)	0 Hold rating(s)	7 Buy rating(s)	3 Strong Buy rating(s)	3.09
Forum Markets	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.50

Larimar Therapeutics has higher earnings, but lower revenue than Forum Markets. Larimar Therapeutics is trading at a lower price-to-earnings ratio than Forum Markets, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Larimar Therapeutics	N/A	N/A	-$165.67M	-$2.06	N/A
Forum Markets	$9.41M	8.49	-$450.52M	-$36.07	N/A

Summary

Larimar Therapeutics beats Forum Markets on 11 of the 15 factors compared between the two stocks.

Get Forum Markets News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding FRMM and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

FRMM vs. The Competition

Export

Metric	Forum Markets	Industry	Manufacturing Sector	NASDAQ Exchange
Market Cap	$79.81M	$3.15B	$5.11B	$12.66B
Dividend Yield	N/A	15.21%	27.49%	8.00%
P/E Ratio	-0.17	13.30	23.85	24.53
Price / Sales	8.49	2,761.98	154.14	96.17
Price / Cash	N/A	26.11	165.86	60.03
Price / Book	0.47	5.15	13.02	6.38
Net Income	-$450.52M	-$35.37M	$116.30M	$331.87M
7 Day Performance	-1.00%	0.68%	-1.03%	0.37%
1 Month Performance	11.40%	0.35%	-0.64%	0.59%
1 Year Performance	N/A	13.83%	9.98%	22.26%

Forum Markets Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
FRMM Forum Markets	3.3203 of 5 stars	$5.96 +1.0%	$10.00 +67.8%	N/A	$79.81M	$9.41M	N/A	7	News Coverage
IRD Opus Genetics	3.0953 of 5 stars	$4.23 flat	$10.77 +154.6%	+246.9%	$349.25M	$14.20M	N/A	14
AMRN Amarin	1.6766 of 5 stars	$16.37 flat	N/A	-12.1%	$343.26M	$213.65M	N/A	360	News Coverage
INDP Indaptus Therapeutics	1.0721 of 5 stars	$3.03 flat	N/A	-78.1%	$343.12M	N/A	N/A	6	Positive News Short Interest Decrease Gap Up
FATE Fate Therapeutics	3.5512 of 5 stars	$2.92 flat	$5.13 +75.5%	+169.6%	$340.35M	$6.65M	N/A	550	News Coverage

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:FRMM) was last updated on 7/12/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Forum Markets (FRMM) Competitors

FRMM vs. IRD, AMRN, INDP, FATE, and LRMR

How does Forum Markets compare to Opus Genetics?

Summary

How does Forum Markets compare to Amarin?

Summary

How does Forum Markets compare to Indaptus Therapeutics?

Summary

How does Forum Markets compare to Fate Therapeutics?

Summary

How does Forum Markets compare to Larimar Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

FRMM vs. The Competition

Forum Markets Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Forum Markets (FRMM) Competitors

FRMM vs. IRD, AMRN, INDP, FATE, and LRMR

How does Forum Markets compare to Opus Genetics?

Do insiders & institutionals believe in FRMM or IRD?

Is FRMM or IRD more profitable?

Do analysts rate FRMM or IRD?

Does the media refer more to FRMM or IRD?

Which has more volatility and risk, FRMM or IRD?

Which has stronger earnings & valuation, FRMM or IRD?

Summary

How does Forum Markets compare to Amarin?

Do institutionals and insiders have more ownership in FRMM or AMRN?

Is FRMM or AMRN more profitable?

Does the media prefer FRMM or AMRN?

Which has higher valuation and earnings, FRMM or AMRN?

Do analysts prefer FRMM or AMRN?

Which has more risk and volatility, FRMM or AMRN?

Summary

How does Forum Markets compare to Indaptus Therapeutics?

Is FRMM or INDP more profitable?

Does the media prefer FRMM or INDP?

Which has preferable valuation & earnings, FRMM or INDP?

Which has more volatility and risk, FRMM or INDP?

Do institutionals & insiders have more ownership in FRMM or INDP?

Do analysts prefer FRMM or INDP?

Summary

How does Forum Markets compare to Fate Therapeutics?

Which has higher valuation and earnings, FATE or FRMM?

Do analysts rate FATE or FRMM?

Is FATE or FRMM more profitable?

Does the media favor FATE or FRMM?

Which has more volatility and risk, FATE or FRMM?

Do institutionals and insiders believe in FATE or FRMM?

Summary

How does Forum Markets compare to Larimar Therapeutics?

Is LRMR or FRMM more profitable?

Do insiders and institutionals believe in LRMR or FRMM?

Does the media favor LRMR or FRMM?

Which has more volatility & risk, LRMR or FRMM?

Do analysts recommend LRMR or FRMM?

Which has preferable earnings & valuation, LRMR or FRMM?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

FRMM vs. The Competition

Forum Markets Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools